Novel targeted therapies in inflammatory breast cancer

Massimo Cristofanilli*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Inflammatory breast cancer (IBC) accounts for 1% to 5% of all breast cancer cases. Its aggressive biology is characterized by rapid disease progression and poor prognosis. To improve and standardize therapy for IBC, development of novel therapeutics to molecular targets of IBC is key. Trastuzumab treatment, an anti-HER2 humanized monoclonal antibody, has been demonstrated to improve the 3-year survival rate of patients with IBC (70.1% vs 53.3%; P = .0007). Another chemotherapeutic drug, lapatinib, a dual tyrosine inhibitor of epidermal growth factor (EGFR) and HER2 signaling, in combination with capecitabine demonstrated encouraging results, with a 51% decrease in disease progression. Further investigation is needed to confirm the efficacy of lapatinib.

Original languageEnglish (US)
Pages (from-to)2837-2839
Number of pages3
JournalCancer
Volume116
Issue numberSUPPL. 11
DOIs
StatePublished - Jun 1 2010

Keywords

  • Chemotherapy
  • HER2
  • Inflammatory breast cancer
  • Lapatinib
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Novel targeted therapies in inflammatory breast cancer'. Together they form a unique fingerprint.

Cite this